8-K filing — BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
Filed: 2026-08-14 AccNo: 0001104659-26-097180 Size: 281 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
8-K filing — BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
Filed: 2026-07-30 AccNo: 0001104659-26-088728 Size: 494 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Jul 30, 2026, 8:30 PM
- Checked
- Jul 30, 2026, 8:30 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Brainstorm Cell Q2 EPS $(0.35) Down From $(0.34) YoY
Brainstorm Cell (OTC:BCLI) reported quarterly losses of $(0.35) per share. This is a 2.94 percent decrease over losses of $(0.34) per share from the same period last year.
Read original at benzingaLunai Bioworks Signs Master Collaboration Agreement With BrainStorm Therapeutics; BioSymetrics Publishes Parkinson's Disease AI White Paper, Initial Data Expected In 1H 2027
New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and
Read original at benzinga